Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear. This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diag...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2015-07, Vol.35 (7), p.4207-4214 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4214 |
|---|---|
| container_issue | 7 |
| container_start_page | 4207 |
| container_title | Anticancer research |
| container_volume | 35 |
| creator | Liang, Yi-Hsin Lin, Yu-Lin Liau, Jau-Yu Tsai, Jia-Huei Liang, Jin-Tung Lin, Been-Ren Hung, Ji-Shiang Tseng, Li-Hui Lin, Liang-In Chang, Yih-Leong Cheng, Ann-Lii Yeh, Kun-Huei |
| description | Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear.
This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011.
The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC.
Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1692755308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1692755308</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-b96cb0990ac056903f4b07cf7e1d4f8056460e666e42ae35c19328431365df663</originalsourceid><addsrcrecordid>eNo1kEtPwzAQhC0kREvhLyAfuUTyI9nExxIeRTQC8ThHjrOhQUkcYkfAv8cV5bTS7DcjzRyRJU8Vj9JEsgU5de6DMQCVyROyEMBFLDO2JHWOfv5ue13Ron3feXqF9Br91PY4eN1Rb2mBXjuvfWtobjs7odk_cj0YnOhT0APp6Ffrd_Thef0SoNoOlAtazHuXHdwZOW505_D8cFfk7fbmNd9E28e7-3y9jUbBuY8qBaZiSjFtWAKKySauWGqaFHkdN1nQYmAIABgLjTIxXEmRxZJLSOoGQK7I5V_uONnPGZ0v-9YZ7Do9oJ1dyUGJNAl7ZAG9OKBz1WNdjqGxnn7K_2XkL2_sXQs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1692755308</pqid></control><display><type>article</type><title>Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Liang, Yi-Hsin ; Lin, Yu-Lin ; Liau, Jau-Yu ; Tsai, Jia-Huei ; Liang, Jin-Tung ; Lin, Been-Ren ; Hung, Ji-Shiang ; Tseng, Li-Hui ; Lin, Liang-In ; Chang, Yih-Leong ; Cheng, Ann-Lii ; Yeh, Kun-Huei</creator><creatorcontrib>Liang, Yi-Hsin ; Lin, Yu-Lin ; Liau, Jau-Yu ; Tsai, Jia-Huei ; Liang, Jin-Tung ; Lin, Been-Ren ; Hung, Ji-Shiang ; Tseng, Li-Hui ; Lin, Liang-In ; Chang, Yih-Leong ; Cheng, Ann-Lii ; Yeh, Kun-Huei</creatorcontrib><description>Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear.
This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011.
The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC.
Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 26124380</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents - therapeutic use ; Cetuximab ; Codon - genetics ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Female ; Humans ; Male ; Middle Aged ; Mutation - genetics ; Neoplasm Metastasis - genetics ; Prognosis ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins - genetics ; Retrospective Studies ; Taiwan ; Young Adult</subject><ispartof>Anticancer research, 2015-07, Vol.35 (7), p.4207-4214</ispartof><rights>Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26124380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liang, Yi-Hsin</creatorcontrib><creatorcontrib>Lin, Yu-Lin</creatorcontrib><creatorcontrib>Liau, Jau-Yu</creatorcontrib><creatorcontrib>Tsai, Jia-Huei</creatorcontrib><creatorcontrib>Liang, Jin-Tung</creatorcontrib><creatorcontrib>Lin, Been-Ren</creatorcontrib><creatorcontrib>Hung, Ji-Shiang</creatorcontrib><creatorcontrib>Tseng, Li-Hui</creatorcontrib><creatorcontrib>Lin, Liang-In</creatorcontrib><creatorcontrib>Chang, Yih-Leong</creatorcontrib><creatorcontrib>Cheng, Ann-Lii</creatorcontrib><creatorcontrib>Yeh, Kun-Huei</creatorcontrib><title>Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear.
This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011.
The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC.
Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cetuximab</subject><subject>Codon - genetics</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation - genetics</subject><subject>Neoplasm Metastasis - genetics</subject><subject>Prognosis</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins p21(ras)</subject><subject>ras Proteins - genetics</subject><subject>Retrospective Studies</subject><subject>Taiwan</subject><subject>Young Adult</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtPwzAQhC0kREvhLyAfuUTyI9nExxIeRTQC8ThHjrOhQUkcYkfAv8cV5bTS7DcjzRyRJU8Vj9JEsgU5de6DMQCVyROyEMBFLDO2JHWOfv5ue13Ron3feXqF9Br91PY4eN1Rb2mBXjuvfWtobjs7odk_cj0YnOhT0APp6Ffrd_Thef0SoNoOlAtazHuXHdwZOW505_D8cFfk7fbmNd9E28e7-3y9jUbBuY8qBaZiSjFtWAKKySauWGqaFHkdN1nQYmAIABgLjTIxXEmRxZJLSOoGQK7I5V_uONnPGZ0v-9YZ7Do9oJ1dyUGJNAl7ZAG9OKBz1WNdjqGxnn7K_2XkL2_sXQs</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Liang, Yi-Hsin</creator><creator>Lin, Yu-Lin</creator><creator>Liau, Jau-Yu</creator><creator>Tsai, Jia-Huei</creator><creator>Liang, Jin-Tung</creator><creator>Lin, Been-Ren</creator><creator>Hung, Ji-Shiang</creator><creator>Tseng, Li-Hui</creator><creator>Lin, Liang-In</creator><creator>Chang, Yih-Leong</creator><creator>Cheng, Ann-Lii</creator><creator>Yeh, Kun-Huei</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201507</creationdate><title>Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations</title><author>Liang, Yi-Hsin ; Lin, Yu-Lin ; Liau, Jau-Yu ; Tsai, Jia-Huei ; Liang, Jin-Tung ; Lin, Been-Ren ; Hung, Ji-Shiang ; Tseng, Li-Hui ; Lin, Liang-In ; Chang, Yih-Leong ; Cheng, Ann-Lii ; Yeh, Kun-Huei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-b96cb0990ac056903f4b07cf7e1d4f8056460e666e42ae35c19328431365df663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cetuximab</topic><topic>Codon - genetics</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation - genetics</topic><topic>Neoplasm Metastasis - genetics</topic><topic>Prognosis</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins p21(ras)</topic><topic>ras Proteins - genetics</topic><topic>Retrospective Studies</topic><topic>Taiwan</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liang, Yi-Hsin</creatorcontrib><creatorcontrib>Lin, Yu-Lin</creatorcontrib><creatorcontrib>Liau, Jau-Yu</creatorcontrib><creatorcontrib>Tsai, Jia-Huei</creatorcontrib><creatorcontrib>Liang, Jin-Tung</creatorcontrib><creatorcontrib>Lin, Been-Ren</creatorcontrib><creatorcontrib>Hung, Ji-Shiang</creatorcontrib><creatorcontrib>Tseng, Li-Hui</creatorcontrib><creatorcontrib>Lin, Liang-In</creatorcontrib><creatorcontrib>Chang, Yih-Leong</creatorcontrib><creatorcontrib>Cheng, Ann-Lii</creatorcontrib><creatorcontrib>Yeh, Kun-Huei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liang, Yi-Hsin</au><au>Lin, Yu-Lin</au><au>Liau, Jau-Yu</au><au>Tsai, Jia-Huei</au><au>Liang, Jin-Tung</au><au>Lin, Been-Ren</au><au>Hung, Ji-Shiang</au><au>Tseng, Li-Hui</au><au>Lin, Liang-In</au><au>Chang, Yih-Leong</au><au>Cheng, Ann-Lii</au><au>Yeh, Kun-Huei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2015-07</date><risdate>2015</risdate><volume>35</volume><issue>7</issue><spage>4207</spage><epage>4214</epage><pages>4207-4214</pages><eissn>1791-7530</eissn><abstract>Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear.
This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011.
The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC.
Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12.</abstract><cop>Greece</cop><pmid>26124380</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2015-07, Vol.35 (7), p.4207-4214 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1692755308 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Cetuximab Codon - genetics Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Female Humans Male Middle Aged Mutation - genetics Neoplasm Metastasis - genetics Prognosis Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Retrospective Studies Taiwan Young Adult |
| title | Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A36%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cetuximab%20Might%20Be%20Detrimental%20to%20Metastatic%20Colorectal%20Cancer%20Patients%20with%20KRAS%20Codon%2012%20Mutations&rft.jtitle=Anticancer%20research&rft.au=Liang,%20Yi-Hsin&rft.date=2015-07&rft.volume=35&rft.issue=7&rft.spage=4207&rft.epage=4214&rft.pages=4207-4214&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1692755308%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1692755308&rft_id=info:pmid/26124380&rfr_iscdi=true |